By Dr Eleni Lagkadinou (Vice President of Oncology Early Development at AbbVie)2024-12-13T10:04:54
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-08T12:00:00Z
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-04-12T15:28:08
Sponsored by nanoComposix
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, By Drug Target Review
Site powered by Webvision Cloud